Status:
RECRUITING
Enhancing Language Function in Primary Progressive Aphasia
Lead Sponsor:
University of Arizona
Conditions:
Primary Progressive Aphasia
Eligibility:
All Genders
45-80 years
Phase:
NA
Brief Summary
This study's goal is to use non-invasive brain stimulation (NBS) techniques to treat language impairment associated with Primary Progressive Aphasia (PPA). The purpose of this study is to combine beha...
Detailed Description
Primary Progressive Aphasia (PPA) is a neurodegenerative disorder that selectively affects language comprehension and/or production, with initial preservation of other cognitive domains. As tDCS has n...
Eligibility Criteria
Inclusion
- diagnosed with PPA by neurologist or speech-language pathologist
- speech-language deficit arising from PPA
- native speaker of English Language or equivalent
- adequate vision (normal or corrected to normal)
- adequate hearing
Exclusion
- meeting (Diagnostic and Statistical Manual) DSM-IV criteria for Axis I mood, anxiety, psychotic or substance abuse disorders.
- highly magnetizable metallic implants, including certain dental work
- neurological disorders besides the ones of interest for the study (e.g., epilepsy)
- Multiple Sclerosis
- Parkinson's Disease
- contraindications for MRI
- pacemakers
- metallic cardiac pumps
- valves
- magnetic materials such as surgical clips, implanted electronic perfusion pumps, or any other condition that would preclude proximity to a strong magnetic field.
- clinically significant claustrophobia
- severe systemic disease (e.g., renal failure)
- poor health
- pregnancy
- epileptic activity in the past 12 months
- family history of epilepsy or other seizure disorders
- brain surgery in the past
- metallic skull plates or implants
- skin lesions or skull damage
- excessive use of alcohol or drugs
- premorbid psychiatric disease affecting communication
- severe non-linguistic cognitive disturbances impeding language therapy
Key Trial Info
Start Date :
August 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 15 2027
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04920318
Start Date
August 30 2021
End Date
June 15 2027
Last Update
November 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arizona
Tucson, Arizona, United States, 85721-0071